



NTRK CONNECT

Annual meeting
Pre-read materials


October 2020

IN PREPARATION FOR OUR VIRTUAL MEETING...



- Register with the COR2ED Engage virtual meeting platform <http://engage.cor2ed.com/register/>
- Complete the pre-meeting survey (available via COR2ED Engage)
- Please review the NTRK CONNECT Educational Objectives for 2020 as part of this pre-read material
 - We will confirm the group’s Educational Objectives for 2021 and would welcome your thoughts and feedback
- Ensure you have Zoom installed on the device you intend to use for the virtual meeting, do share your video
 - Any guidance required please let us know @iain.murdoch@cor2ed.com
- Identify a suitable location from which to join us at
 - **17:00 CET (11:00 EST) for 1.5 hours on Friday 8th October**
 - A quiet location is preferred so that you do not need to self-mute and can therefore actively contribute to our group discussion.... See you there!

MEETING OBJECTIVES



- Review the educational programmes delivered in 2020 and the impact achieved
- Define key objectives, topics and formats for educational programmes in 2021
- Discuss ways of working and expansion plans for future membership

MEETING AGENDA - THURSDAY 8th OCTOBER


(16:00-17:30 London, 17:00-18:30 Amsterdam, 11:00-12:30 New York)



Time (BST)	Topic	Facilitator
16:00-16:05	Welcome and today's agenda	Iain
16:05-16:20	Review our 2020 educational programme and impact achieved	Iain & Mahir
16:20 - 17:15	Define our educational objectives and key topics to be addressed in 2021 programme	Iain & Mahir
17:15 - 17:30	Ways of working, new initiatives and extending membership	Iain


STRATEGIC OBJECTIVES IN 2020

1. NTRK CONNECT's **unique approach**: translating the latest science into the context of clinical practice
2. Ensuring NTRK CONNECT resources are THE reference for all HCPs – a 'go to' online platform providing **foundational and valued educational content** on **NTRK fusion positive cancer** and **TRK inhibition**



TRANSLATE THE LATEST SCIENCE INTO CLINICAL PRACTICE

OUR 2020 EDUCATIONAL OBJECTIVES




The 3 objectives we agreed on were to educate on:


1. *NTRK* fusions as a primary oncogenic driver, the **importance of testing and diagnosis**
2. **TRK fusion proteins** and **TRK fusion cancer**: the implications for clinical practice
3. **TRK Inhibition**: Educate on Mechanism of Action and implementation in clinical practice for a broad range of tumour types

Please review these objectives and come prepared to discuss educational objectives for **2021...**

OUR 2020 EDUCATIONAL PROGRAMME



✓ Completed
* In development



PROGRAMME PERFORMANCE METRICS

NTRK CONNECT: 12 MONTH PERFORMANCE

REACH

How **many** of the target audience are reached?



Website & Newsletter Reach

6,210 ↑

Total Website Visits

44,046

No. HCPs Reached Via Email

4,781 ↑

Unique Website Visitors

4,431 ↑

New Visitors to Website



Social Media Reach

368 ↑

+19
Twitter Followers

88,397 ↑

Impressions

ENGAGEMENT

How **interested** is the target audience?



Website Engagement

11,517 ↑

Website Page Views

1,779 ↑

Website Return Visits

726 ↑

Returning Visitors to Website

Programme Engagement



73,561

Unique Email Opens

15.9%

Email Open Rate

2,305 ↑

Slide Downloads

2,238 ↑

Videos Viewed

58.2% ↑

Avg. % Video Watched



Social Media Engagement

438 ↑

Likes

206 ↑

Shares/Retweets

1.7% ↑

Twitter Avg. Engagement Rate

IMPACT

What **educational outcomes** have the programmes delivered?



84%

Valuable

CME Outcome Level*

2



82%

Knowledge Improving

3A



73%

Practice Changing

4



0%


Performance Changing

5

Highest of all CONNECT groups

SIX EDUCATIONAL PROGRAMMES DELIVERED TO DATE IN 2020

1. Clinical topic newsletters



Molecular subtypes in paediatric and adult sarcomas, including clinical implications of *CIC-DUX4*, *NTRK* gene fusions and *SDH*-deficient *GIST*

Watch the video and download the slides


Prof. George Demetri
SARCOMA CONNECT

NTRK CONNECT have partnered with SARCOMA CONNECT to describe a number of the molecular subtypes that exist in paediatric and adult sarcomas. This includes a spotlight on the potential indicators that may hint at the presence of

- Video newsletter and accompanying slides
- Achieved a high open rate of 21.3% (>10K opens)
- 666 video views, 257 slide deck downloads

1 more to be issued in Q4

2. Key Publication Snapshots



Newsletter June 2020

NTRK connect®
POWERED BY COR2ED

Key Publication Snapshot 2 – Identifying patients with *NTRK* fusion cancer

Larotrectinib Selective TRK inhibitor

Adults Phase 1 + Children Phase 1/2 + Adults/Children Phase 2

159 patients

0.03 to 47.2 months

Adults + children with TRK fusion positive cancer


Approximate change in number size of TRK fusion growth

mDoR 35.2 months, mPFS 28.3 months, mOS 44.4 months, ORR 79%

- 5 Key Publication Snapshots developed through 2020 (3 delivered)
- Spotlight on key papers, educational content provided in a number of formats

2 more to be issued in Q4

3. Update from ASCO and ESMO



Prof. Ezra Cohen
NTRK CONNECT

NTRK Fusion Cancer
by Prof. Ezra Cohen
Moores Cancer Center
San Diego CA, USA

Watch the video and download the slides

Prof. Viktor Grünwald
NTRK CONNECT

NTRK Fusion Positive Cancer
by Prof. Viktor Grünwald
University Hospital Essen,
Germany

Watch the video and download the slides

- Updates covering selected abstracts
- Significant number of downloads and social interactions achieved

CLINICAL TOPIC NEWSLETTER 1: MOLECULAR SUBTYPES IN PAEDIATRIC & ADULT SARCOMAS

In collaboration with  sarcoma connect®
POWERED BY COR2ED

Distributed between
8th April – 21st April



26,139

Total HCPs Reached



10,842

Unique Email Opens



21.3%

Avg. Open Rate



257

Slide Downloads



666

Video Views



360


Social Media Views



34

Social Media Engagements

CME Outcome Level*: 1



Newsletter April 2020

 NTRK connect®
POWERED BY COR2ED

Molecular subtypes in paediatric and adult sarcomas, including clinical implications of *CIC-DUX4*, *NTRK* gene fusions and SDH-deficient GIST

[Watch the video and download the slides](#)


Prof. George Demetri
SARCOMA CONNECT

NTRK CONNECT have partnered with SARCOMA CONNECT to describe a number of the molecular subtypes that exist in paediatric and adult sarcomas. This includes a spotlight on the potential indicators that may hint at the presence of *NTRK* gene fusions.

Prof George Demetri (SARCOMA CONNECT) has developed this resource with COR2ED.

Brought to you by:


Prof. George Demetri MD,
Dana-Farber Cancer Institute, USA

Prof. George Demetri

*Moore DE, et al. J. Contin Educ Health Prof. 2009; 29(1):1-15. Please see appendix to this deck for additional information

KEY PUBLICATION SNAPSHOT 1: LAROTRECTINIB & ENTRECTINIB EFFICACY & SAFETY

Distributed between
11th May – 22nd May



25,681

Total HCPs Reached



6,691

Unique Email Opens



13.1%

Avg. Open Rate



211

Slide Downloads



432

Video Views



8,633

Social Media Views



542

Social Media Engagements



89

Infographic Downloads
Hong 49, Doebele 40

CME Outcome Level*: 4




77%
Valuable



62%
Knowledge
Improving



46%
Practice
Changing



Newsletter May 2020

NTRK connect
POWERED BY COR2ED

Key Publication Snapshot 1 – Larotrectinib and Entrectinib efficacy and safety profile in solid tumours

Watch the video and download slides

Prof. Andrea Sartore-Bianchi
NTRK CONNECT

NTRK CONNECT is developing a series of Publication Snapshots. Throughout 2020, we will be issuing five Snapshots putting the spotlight on landmark publications and new developments relating to *NTRK* gene fusions testing and TRK inhibitor therapies. This first Publication Snapshot focusses on two recent papers

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Hong DS, et al. *Lancet Oncol* 2020; 21:531-40

Larotrectinib
Selective TRK inhibitor

Phase	Adults Phase 1	Children Phase 1/2	Adults/Children Phase 2
Patients	159 patients		
Durations of treatment	0.03 to 47.2 months		

mDoR: 35.2 months, mPFS: 28.3 months, mOS: 44.4 months, ORR: 79%

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Doebele RC, et al. *Lancet Oncol* 2020; 21:271-82

Entrectinib
TRK, ROS1- and ALK-inhibitor

Phase	ALKA-372-001 Phase 1	STARTRK-1 Phase 1/2	STARTRK-2 Phase 2
Patients	54 patients		
Median treatment duration	7.85 months (IQR 3.68-12.71)		

mDoR: 10.4 months, mPFS: 11.2 months, mOS: 21 months, ORR: 57%

Prof. Andrea Sartore-Bianchi

*Moore DE, et al. *J. Contin Educ Health Prof.* 2009; 29(1):1-15. Please see appendix to this deck for additional information

KEY PUBLICATION SNAPSHOT 2: IDENTIFYING PATIENTS WITH *NTRK* FUSION POSITIVE CANCER

Distributed between
3rd June – 17th June



23,798

Total HCPs Reached



7,643

Unique Email Opens



16.2%

Avg. Open Rate



183

Slide Downloads



340

Video Views



3,219

Social Media Views



293

Social Media Engagements



82

Infographic Downloads

CME Outcome Level*: 4




100% Valuable



100% Knowledge Improving



100% Practice Changing



Newsletter June 2020

NTRK connect
POWERED BY COR2ED

Key Publication Snapshot 2 – Identifying patients with *NTRK* fusion cancer

Watch the video and access downloadable resources

Prof. Fernando López-Ríos
NTRK CONNECT

NTRK CONNECT is developing a series of Publication Snapshots. In June 2020, we will be issuing five Snapshots with a spotlight on new diagnostic and new developments relating to *NTRK* gene fusions and their potential therapeutic applications. This second Publication Snapshot provides an overview of the diagnostic methods available and proposes histology-based and genomic-based triage algorithms. You can access and download the content of this snapshot including a one-page infographic as well as a detailed form.

Prof. Fernando López-Ríos (NTRK CONNECT) has discussed this content at the COR2ED Summit.

Brought to you by:

Identifying patients with *NTRK* fusion cancer
Solomon JP, et al. Ann. Oncol. 2019;30 (Suppl_8):viii16-viii22

NTRK gene fusions

5' upstream gene partner

3' *NTRK1*, *NTRK2* or *NTRK3*

NTRK testing methods

	XXXX	XXXX	Expression
IHC	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
FISH	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
RT-PCR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
DNA/RNA-based NGS	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Histology-based triage

- Low pretest probability that the tumour has *NTRK* fusion: Sarcoma, Carcinoma, glioma, melanoma. Pathways: RNA-level fusion testing (panel), Genomic-based triage.
- High pretest probability that the tumour has *NTRK* fusion: Carcinoma, Sarcoma. Pathways: Pan-*NTRK* IHC, FISH or RNA-level fusion testing. Outcomes: Positive (NTRK fusion positive), Negative (FISH or RNA-level fusion testing).

Genomic-based triage

- Carcinoma, glioma, melanoma: Cancer gene Panel testing. Outcomes: Driver negative (Enrichment for *NTRK* fusion, Screen for *NTRK* fusion), Low tumour mutation burden (Screen for *NTRK* fusion).
- Example 1: Lung carcinoma: Sporadic MSI-H (Screen for *NTRK* fusion).
- Example 2: Colorectal carcinoma: Sporadic MSI-H (Screen for *NTRK* fusion).

DNA, deoxyribonucleic acid; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry; MSI-H, microsatellite instability-high; NGS, next-generation sequencing; RNA, ribonucleic acid; RT-PCR, reverse transcription polymerase chain reaction; TRK, tropomyosin receptor kinase; NTRK, neurotrophic tyrosine receptor kinase. This content is supported by an Independent Educational Grant from Bayer. For more information please visit: www.ntrkconnect.info June 2020

Prof. Fernando López-Ríos

*Moore DE, et al. J. Contin Educ Health Prof. 2009; 29(1):1-15. Please see appendix to this deck for additional information
Social Media Engagements include Like, Share or Retweet
Data to 30th June 2020

UPDATE FROM ASCO 2020

NTRK UPDATE PERFORMANCE WELL VS OTHER CONNECT GROUPS



Dr. Shubham Pant
GI CONNECT
GI Cancer

Valuable: 82%
Knowledge improving: 79%
Practice Changing: 71%

Video views:
343

Slide downloads:
378

Social Media Impressions
8,847



Dr. Amit Singal
HCC CONNECT
Liver Cancer

Valuable: 94%
Knowledge improving: 97%
Practice Changing: 84%

Video views:
292

Slide downloads:
291

Social Media Impressions
6,910



Prof. Sandy Srinivas
GU CONNECT
GU Cancer

Valuable: 100%
Knowledge improving: 97%
Practice Changing: 84%

Video views:
368

Slide downloads:
338

Social Media Impressions
2,962



Prof. Ezra Cohen
NTRK CONNECT
NTRK Fusion Cancer

Valuable: 83%
Knowledge improving: 88%
Practice Changing: 83%

Video views:
260

Slide downloads:
191

Social Media Impressions
8,662



Brittini Prosdocimo, MSN, RN, BMTCTN
GI Nurses CONNECT
GI and Liver Cancer Nursing

Valuable: 95%
Knowledge improving: 95%
Practice Changing: 86%

Video views:
212

Slide downloads:
88

Social Media Impressions
448



Joanne Chien, MSN, RN, GNP-BC
GU Nurses CONNECT
GU Cancer Nursing

Valuable: 100%
Knowledge improving: 100%
Practice Changing: 100%

Video views:
72



Slide downloads:
17

Social Media Impressions
1,164

ESMO ONCOLOGY PRO X2 MODULES: TARGETING *NTRK* GENE FUSIONS



- **23,937 unique visits** (10 months)
 - 2,394 unique visits per month




1st April to 30th June 2020

Unique visit = unique view of homepage for educational resource within ESMO OncologyPro portal


NTRK COMMUNITY ON TWITTER

Building a community of oncologists, pathologists, patients associations and industry all focused on *NTRK* gene fusions

Number of followers:
Sept 2019 - Sept 2020



Impressions
Sept 2019 – Sept 2020



Top Tweets in May, June and July 2020

ntkrconnectinfo @ntkrconnectinfo · May 25
 Infographic of **#larotrectinib** and **#entrectinib** : 2 approved **#NTRK** gene fusions from our **#publication #snapshot #series**. For more information visit: ntkrconnect.info/ntkr-connect-k... **#precisionmedicine #oncology #MedEd** Do you like it? tell us, we will provide this format for the next paper pic.twitter.com/JP7Tpn02a8

2,991 356 11.9%

ntkrconnectinfo @ntkrconnectinfo · Jun 8
 Infographic of **#NTRK** gene fusions testing methods and diagnostic approach in solid tumours from our **#publication #snapshot #series** by Prof. López-Ríos. For more information visit: ntkrconnect.info/key-publicatio... **#precisionmedicine #oncology #MedEd** Do you like it? tell us! Follow us! pic.twitter.com/pCxDEzlege

1,413 134 9.5%

ntkrconnectinfo @ntkrconnectinfo · Jul 2
#WorldGI2020 Woouah!! today during the highlights of Day 1 of the congress, Dr Josep Tabernero summarised 8 key presentations from Day 1 among them he highlighted the 2 presentations on **#NTRK** gene fusions!!! Identifying NTRK fusion positive patients is key! **#PrecisionMedicine** pic.twitter.com/dfKn1TtbWF

3,340 201 6.0%



NTRK CONNECT
Bodenackerstrasse 17
4103 Bottmingen
SWITZERLAND

Dr. Froukje Sosef MD

+31 6 2324 3636

froukje.sosef@cor2ed.com

Dr. Antoine Lacombe Pharm D, MBA

+41 79 529 42 79

antoine.lacombe@cor2ed.com



Heading to the heart of Independent Medical Education Since 2012